Insider Selling: BioSyent Inc. (CVE:RX) Director Sells 2,320 Shares of Stock

BioSyent Inc. (CVE:RX) Director Seyed Ahmad Ashrafi sold 2,320 shares of the firm’s stock in a transaction on Friday, September 20th. The shares were sold at an average price of C$10.95, for a total transaction of C$25,404.00.

BioSyent Stock Performance

RX opened at C$11.00 on Thursday. The stock has a market capitalization of C$127.49 million, a price-to-earnings ratio of 18.33 and a beta of 0.93. The company has a fifty day moving average of C$10.39 and a 200 day moving average of C$9.53. BioSyent Inc. has a fifty-two week low of C$7.66 and a fifty-two week high of C$11.45. The company has a debt-to-equity ratio of 3.19, a quick ratio of 6.91 and a current ratio of 6.13.

BioSyent (CVE:RX) last posted its earnings results on Monday, August 26th. The company reported C$0.13 earnings per share for the quarter, meeting the consensus estimate of C$0.13. The company had revenue of C$8.95 million during the quarter, compared to analysts’ expectations of C$8.80 million. BioSyent had a net margin of 21.14% and a return on equity of 20.88%. As a group, sell-side analysts forecast that BioSyent Inc. will post 0.6785935 earnings per share for the current fiscal year.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.